Literature DB >> 2657246

Immunomodulation with thymopentin: in vitro studies.

J Duchateau1, K Bolla.   

Abstract

Immunomodulation is interpreted as a temporary alert in a certain part of the immune system. The activation of immune competent cells is presented as a possible basic mechanism of this phenomenon. In the absence of a primary stimulus, immunomodulation remains physiologically silent, but it results in a modified immune response if the corresponding targets are being stimulated. For practical reasons it is suggested that distinctions be made between preventive and regulative immunomodulation. The PWM-induced IgG production of PBMCs was used as a model for the demonstration of the modulatory effect of thymopentin in vitro. Depending on the concentration of thymopentin used in the cultures, this pentapeptide can either stimulate or inhibit the induced IgG production. It also influences PGE2 production and catabolism in the cultures stimulated with PWM. Indomethacin abolishes the modulatory effect of thymopentin on IgG production in this model. It is suggested that the possibility of interactions between an immune modulator and therapeutic approaches which can influence the proportions or functions of the corresponding target cells be considered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657246     DOI: 10.1007/bf02985219

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  17 in total

Review 1.  Lymphocyte activation.

Authors:  H J Wedner; C W Parker
Journal:  Prog Allergy       Date:  1976

2.  Thymopoietin enhances the allogeneic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes.

Authors:  G H Sunshine; R S Basch; R G Coffey; K W Cohen; G Goldstein; J W Hadden
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

3.  Electrophysiological changes similar to those of myasthenia gravis in rats with experimental autoimmune thymitis.

Authors:  G Goldstein; W W Hofmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-10       Impact factor: 10.154

4.  Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.

Authors:  P Franchimont; C Hauwaert; K Bolla
Journal:  Surv Immunol Res       Date:  1985

5.  Experience with thymopentin in the treatment of periarthritis humeroscapularis, tendinitis, and gonarthrosis by local infiltration.

Authors:  F Pipino; D Vittore
Journal:  Arzneimittelforschung       Date:  1988-01

6.  Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study.

Authors:  M G Malaise; C Hauwaert; P Franchimont; B Danneskiold-Samsoe; R Bach-Andersen; D Gross; H Gerber; H Gerschpacher; H Stocker; K Bolla
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

7.  Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides.

Authors:  T Audhya; D H Schlesinger; G Goldstein
Journal:  Biochemistry       Date:  1981-10-13       Impact factor: 3.162

8.  Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Authors:  T Audhya; M P Scheid; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Cooperativity of thymopoietin 32-36 (the active site) and thymopoietin 38-45 in receptor binding.

Authors:  T Audhya; G A Heavner; D J Kroon; G Goldstein
Journal:  Regul Pept       Date:  1984-10

10.  Structural requirements for the biological activity of thymopentin analogs.

Authors:  G A Heavner; T Audhya; D Kroon; G Goldstein
Journal:  Arch Biochem Biophys       Date:  1985-10       Impact factor: 4.013

View more
  1 in total

Review 1.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.